Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Open-label Study of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma
jRCT2061220078Phase 2Completed
- Sponsor
- Takeda
- Start
- Oct 2017
- Modality
- Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of modakafusp alfa in multiple myeloma (MM) (12 arms), sponsored by Takeda. Primary endpoints: Percentage of Participants Reporting One or More Treatment Emergent Adverse Events (TEAEs) - Part 1, Number of Participants With Dose-limiting Toxicities (DLTs) - Part 1 and 10 more. Started Oct 2017; status: completed.
02
Drugs
modakafusp alfa
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2061220078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061220078.